206 related articles for article (PubMed ID: 30732592)
1. Patterns and trends of utilization of incretin-based medicines between 2008 and 2014 in three Italian geographic areas.
Roberto G; Barone-Adesi F; Giorgianni F; Pizzimenti V; Ferrajolo C; Tari M; Bartolini C; Da Cas R; Maggini M; Spila-Alegiani S; Francesconi P; Trifirò G; Poluzzi E; Baccetti F; Gini R
BMC Endocr Disord; 2019 Feb; 19(1):18. PubMed ID: 30732592
[TBL] [Abstract][Full Text] [Related]
2. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
Ou HT; Chang KC; Li CY; Wu JS
Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
[TBL] [Abstract][Full Text] [Related]
3. Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan.
Chang CY; Yeh YH; Chan YH; Liu JR; Chang SH; Lee HF; Wu LS; Yen KC; Kuo CT; See LC
Cardiovasc Diabetol; 2017 Dec; 16(1):159. PubMed ID: 29258504
[TBL] [Abstract][Full Text] [Related]
4. Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany-A retrospective analysis of real-world data.
Dombrowski S; Kostev K; Jacob L
Osteoporos Int; 2017 Aug; 28(8):2421-2428. PubMed ID: 28455750
[TBL] [Abstract][Full Text] [Related]
5. Use of incretin agents and risk of acute and chronic pancreatitis: A population-based cohort study.
Knapen LM; de Jong RG; Driessen JH; Keulemans YC; van Erp NP; De Bruin ML; Leufkens HG; Croes S; de Vries F
Diabetes Obes Metab; 2017 Mar; 19(3):401-411. PubMed ID: 27883260
[TBL] [Abstract][Full Text] [Related]
6. Dipeptidyl peptidase-4 inhibitors lower the risk of autoimmune disease in patients with type 2 diabetes mellitus: A nationwide population-based cohort study.
Seong JM; Yee J; Gwak HS
Br J Clin Pharmacol; 2019 Aug; 85(8):1719-1727. PubMed ID: 30964554
[TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for new-onset gastric cancer and gastric diseases in patients with type 2 diabetes mellitus: a population-based cohort study.
Chou OHI; Chauhan VK; Chung CTS; Lu L; Lee TTL; Ng ZMW; Wang KKW; Lee S; Liu H; Pang RTK; Kaewdech A; Cheung BMY; Tse G; Zhou J
Gastric Cancer; 2024 Jun; ():. PubMed ID: 38856768
[TBL] [Abstract][Full Text] [Related]
8. Comparison of effectiveness and drug cost between dipeptidyl peptidase-4 inhibitor and biguanide as the first-line anti-hyperglycaemic medication among Japanese working generation with type 2 diabetes.
Ihana-Sugiyama N; Sugiyama T; Tanaka H; Ueki K; Kobayashi Y; Ohsugi M
J Eval Clin Pract; 2020 Feb; 26(1):299-307. PubMed ID: 31161662
[TBL] [Abstract][Full Text] [Related]
9. The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors.
Ling AW; Chan CC; Chen SW; Kao YW; Huang CY; Chan YH; Chu PH
Cardiovasc Diabetol; 2020 Nov; 19(1):188. PubMed ID: 33158436
[TBL] [Abstract][Full Text] [Related]
10. Dipeptidyl peptidase-4 inhibitor use is not associated with elevated risk of severe joint pain in patients with type 2 diabetes: a population-based cohort study.
Hou WH; Chang KC; Li CY; Ou HT
Pain; 2016 Sep; 157(9):1954-1959. PubMed ID: 27127847
[TBL] [Abstract][Full Text] [Related]
11. The association of dipeptidyl peptidase IV inhibitors and other risk factors with bullous pemphigoid in patients with type 2 diabetes mellitus: A retrospective cohort study.
Guo JY; Chen HH; Yang YC; Wu PY; Chang MP; Chen CC
J Diabetes Complications; 2020 Mar; 34(3):107515. PubMed ID: 31932172
[TBL] [Abstract][Full Text] [Related]
12. Risk of lower limb amputation in diabetic patients using SGLT2 inhibitors
Lu Y; Guo C
Ther Adv Drug Saf; 2023; 14():20420986231178126. PubMed ID: 37332886
[TBL] [Abstract][Full Text] [Related]
13. Use of Dipeptidyl-Peptidase-4 Inhibitors and the Risk of Pneumonia: A Population-Based Cohort Study.
Wvan der Zanden R; de Vries F; Lalmohamed A; Driessen JH; de Boer A; Rohde G; Neef C; den Heijer C
PLoS One; 2015; 10(10):e0139367. PubMed ID: 26468883
[TBL] [Abstract][Full Text] [Related]
14. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study.
Kim SC; Schneeweiss S; Glynn RJ; Doherty M; Goldfine AB; Solomon DH
Ann Rheum Dis; 2015 Nov; 74(11):1968-75. PubMed ID: 24919467
[TBL] [Abstract][Full Text] [Related]
15. Dipeptidyl peptidase-4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular and renal outcomes in a propensity-matched cohort study.
Kim KJ; Choi J; Lee J; Bae JH; An JH; Kim HY; Yoo HJ; Seo JA; Kim NH; Choi KM; Baik SH; Kim SG; Kim NH
Cardiovasc Diabetol; 2019 Mar; 18(1):28. PubMed ID: 30857540
[TBL] [Abstract][Full Text] [Related]
16. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
Deacon CF; Mannucci E; Ahrén B
Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
[TBL] [Abstract][Full Text] [Related]
17. Dipeptidyl Peptidase 4 Inhibitors and Risk of Inflammatory Bowel Disease: Real-world Evidence in U.S. Adults.
Wang T; Yang JY; Buse JB; Pate V; Tang H; Barnes EL; Sandler RS; Stürmer T
Diabetes Care; 2019 Nov; 42(11):2065-2074. PubMed ID: 31471377
[TBL] [Abstract][Full Text] [Related]
18. Use of dipeptidyl peptidase-4 inhibitors is associated with a lower risk of rheumatoid arthritis in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of cohort studies.
Charoenngam N; Rittiphairoj T; Ponvilawan B; Ungprasert P
Diabetes Metab Syndr; 2021; 15(1):249-255. PubMed ID: 33465685
[TBL] [Abstract][Full Text] [Related]
19. Dipeptidyl peptidase-4 inhibitor treatment could decrease
Chen HH; Chen CC; Ho CW; Hsieh MC; Hsu SP; Lin CL; Kao CH
Postgrad Med; 2020 Nov; 132(8):714-719. PubMed ID: 32633173
[TBL] [Abstract][Full Text] [Related]
20. Effects of dipeptidyl peptidase-4 inhibitor treatment doses on tuberculosis in patients with diabetes: a long-term nationwide population-based cohort study.
Chen HH; Hsieh MC; Ho CW; Chen CC; Hsu SP; Lin CL; Kao CH
Ann Palliat Med; 2020 Sep; 9(5):2817-2825. PubMed ID: 32787376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]